Formal mechanistic studies in RCC models—as well as other solid tumour indications—are required to more fully define the precise cellular circuits engaged by GPR65, as well as their interplay with angiogenic and metabolic pathways. This evidence concerns the gene GPR65 and renal cell carcinoma.